ICI
-
Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy
By Kara Nyberg, PhD Posted: June 24, 2020 Pneumonitis is a well-known complication associated with immune checkpoint inhibitors (ICI). A collaborative effort between the U.S. Food and Drug Administration (FDA) […]
-
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […]
-
Doctor of Nursing Practice Project Aims to Educate Non-Oncology Providers About the Management of Immunotherapy AEs
By Enza Esposito Nguyen, DNP, RN, ANP-BC Posted: February 12, 2020 Dr. Enza Esposito Nguyen Although we continue to see many immunotherapy clinical trials mature and deliver marvelous improvements […]
-
Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC
This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on patients with poor performance status. […]
-
Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab
By Suresh Ramalingam, MD Posted: December 11, 2019 IN REFERENCE TO: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non–Small-Cell Lung Cancer Treated […]
-
Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data
Posted: November 12, 2019 Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking PACIFIC data in new directions. […]
View ILCN Archives
Provider Resources